Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.40 |
| ▸ | ACHE | P22303 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25480233 | 0.91 | HRH3 (0.44) | NCF1HRH3KCNH2 | |
| SCHEMBL25569155 | 0.90 | NCF1 (0.42) | NCF1HRH3ACHEHRH4SLC6A4 | |
| SCHEMBL12890856 | 0.89 | HRH3 (0.43) | HRH3KCNH2 | |
| SCHEMBL757866 | 0.83 | NCF1 (0.62) | NCF1HRH3ACHEHRH4 | |
| SCHEMBL25630382 | 0.83 | NCF1 (0.43) | NCF1HRH3ACHE | |
| SCHEMBL24501875 | 0.83 | HRH3 (0.40) | HRH3KCNH2 | |
| SCHEMBL27323580 | 0.83 | HRH3 (0.40) | HRH3KCNH2 | |
| SCHEMBL8364993 | 0.83 | HRH3 (0.40) | HRH3ACHEKCNH2 | |
| SCHEMBL23134084 | 0.81 | HRH3 (0.42) | HRH3ACHEKCNH2 | |
| SCHEMBL16304071 | 0.79 | GNAI3 (0.39) | NCF1HRH3ACHEKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023069514-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | NCF1 3314/4885HRH3 531/4885ACHE 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.